Cosmetic cross-reference Noindex: medium evidence

Aniline

CAS 62-53-3

Aniline (CAS 62-53-3) is a pharmaceutical compound with 2 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
2
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Aniline
CAS Number
62-53-3
UNII
SIR7XX2F1K
InChIKey
PAYRUJLWNCNPSJ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL538
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE ChEMBL 36 activities + assays 2 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 847.6333333333333 nM 3 -
- EC50 9400 nM 1 -
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Aniline used for in pharmaceutical contexts?

Aniline (CAS 62-53-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Aniline?

No adverse-event association or SIDER side-effect rows are rendered for Aniline in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Aniline also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for ANILINE with EU status "restricted".

What clinical phase is Aniline in?

No phase 1-4 clinical development badge is rendered for Aniline because the matched compound identifier rows do not contain a max-phase value.